Company news
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) news
Karyopharm Therapeutics Inc. news releases on 6ix. Latest, Jun 1, 2024: Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study…
Press releases — page 2
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates
May 31, 2024
Karyopharm to Participate at the Jefferies Global Healthcare Conference
May 28, 2024
Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare Conference
May 7, 2024
Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
May 7, 2024
Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029
May 7, 2024
Karyopharm to Report First Quarter 2024 Financial Results on May 8, 2024
May 1, 2024
Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting
April 23, 2024
Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences
March 5, 2024
Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
February 28, 2024
Karyopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024
February 21, 2024
Karyopharm Announces Preliminary Unaudited 2023 Revenue and 2024 Objectives
January 7, 2024
Karyopharm to Present at 42nd Annual J.P. Morgan Healthcare Conference
January 2, 2024
Karyopharm Shares Data at ASH 2023 Showing Strong SVR and TSS Durability Observed from Phase 1 Study of Selinexor 60mg and Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Myelofibrosis Patients, with no SVR or TSS Progressions Observed As of the Data Cutoff(1)
December 9, 2023
Karyopharm Announces New Preliminary Data in Overall Survival (OS) in Selinexor-Treated Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer as Part of Pre-Specified Exploratory Subgroup Analysis of the SIENDO Study
November 5, 2023
Karyopharm Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
November 1, 2023
Karyopharm Announces Presentations at the 65th American Society of Hematology Annual Meeting and Exposition (ASH)
November 1, 2023
Karyopharm Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Novel CELMoD™ Agent CC- 92480 Mezigdomide in Combination with Selinexor in Patients with Relapsed/Refractory Multiple Myeloma
October 29, 2023
Karyopharm to Report Third Quarter 2023 Financial Results on November 2, 2023
October 25, 2023
Karyopharm to Present Selinexor Data at the 2023 International Myeloma Society Annual Meeting and European Society of Gynaecological Oncology 2023 Annual Meetings
September 25, 2023
Karyopharm Appoints Zhen Su, MD, MBA to its Board of Directors
August 31, 2023
Karyopharm Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
August 1, 2023
Karyopharm to Report Second Quarter 2023 Financial Results on August 2, 2023
July 25, 2023
Karyopharm Announces Presentation of Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer
July 24, 2023
Karyopharm Announces Updated Exploratory Subgroup Analysis from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer to be Presented at ASCO Plenary Series on July 25th
July 18, 2023
Karyopharm Receives FDA Fast Track Designation for Selinexor for the Treatment of Myelofibrosis
July 16, 2023
Karyopharm Initiates Pivotal Phase 3 Study of XPO1 Inhibitor Selinexor and Ruxolitinib in JAK Inhibitor (JAKi) Naïve Myelofibrosis
June 27, 2023
Karyopharm to Participate at the Jefferies Healthcare Conference
May 31, 2023
Karyopharm to Present New Selinexor Data at the 2023 American Society of Clinical Oncology and European Hematology Association Annual Meetings
May 22, 2023
Karyopharm Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
May 3, 2023
Karyopharm Announces Presentation of Interim Data from Phase 2 Study of Single-Agent Eltanexor in Relapsed/Refractory (R/R) Higher-Risk Myelodysplastic Neoplasms (MDS) at 17th International Congress on MDS
May 2, 2023
Karyopharm to Report First Quarter 2023 Financial Results on May 4, 2023
April 30, 2023
Karyopharm Announces Presentation of Updated Phase 1 Selinexor Data in Patients with Treatment-Naïve Myelofibrosis at AACR 2023
April 17, 2023
Karyopharm Announces Updated Selinexor Data in Patients with Treatment-Naïve Myelofibrosis to be Presented at AACR 2023
March 13, 2023
Karyopharm and Menarini Group Receive Full Marketing Authorization from the UK Medicines & Healthcare Products Regulatory Agency for NEXPOVIO® (selinexor) in Combination with Bortezomib and Dexamethasone for the Treatment of Adult Patients with Multip...
February 20, 2023
Karyopharm Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress
February 14, 2023
Karyopharm to Report Fourth Quarter and Full Year 2022 Financial Results on February 15, 2023
February 7, 2023
Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue and Outlines 2023 Objectives
January 8, 2023
Karyopharm Announces Presentation of Updated Phase 1 Selinexor Data in Patients with Treatment-Naïve Myelofibrosis at ASH 2022
December 11, 2022
Karyopharm Announces $165 Million Private Placement
December 4, 2022
Karyopharm Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
November 2, 2022
Karyopharm and Menarini Group Announce Orphan Medicinal Product Designation from the European Commission for Selinexor for the Treatment of Myelofibrosis
October 31, 2022
Karyopharm Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress
August 3, 2022
Karyopharm and Menarini Group Receive Full Marketing Authorisation from the European Commission for NEXPOVIO® (selinexor) for the Treatment of Patients with Multiple Myeloma After at Least One Prior Therapy
July 20, 2022
Karyopharm Granted Regulatory Designations for Eltanexor for the Treatment of Myelodysplastic Syndromes
July 19, 2022
Karyopharm and Menarini Group Receive Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma
May 19, 2022
Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the European Hematology Association 2022 Hybrid Congress
May 11, 2022
Karyopharm to Report First Quarter 2022 Financial Results on May 5, 2022
April 27, 2022
Karyopharm Announces Selinexor Data to be Presented at the 2022 American Society of Clinical Oncology Annual Meeting
April 26, 2022
Karyopharm Announces Further Transition of Co-Founders Sharon Shacham PhD, MBA and Michael Kauffman, MD, PhD and appointment of Reshma Rangwala, MD, PhD as Chief Medical Officer
March 28, 2022
Karyopharm Announces Upcoming Presentations of Phase 3 SIENDO Study of Selinexor in Patients with Advanced or Recurrent Endometrial Cancer
March 15, 2022